Pharmaceutical News RSS Feed - Pharmaceutical News

Study shows epilepsy drug can protect vision of MS patients

Study shows epilepsy drug can protect vision of MS patients

A drug commonly taken to prevent seizures in epilepsy may surprisingly protect the eyesight of people with multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015. [More]
Researchers explore benefits and risks of biosimilar antibodies

Researchers explore benefits and risks of biosimilar antibodies

In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options. [More]
Aspirin use continues to surge among older adults in US

Aspirin use continues to surge among older adults in US

A national survey suggests that slightly more than half of the older adults in the United States are now taking a daily dose of aspirin, even though its use is not recommended by the Food and Drug Administration for most people who have not yet had a heart attack or stroke. [More]
Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A. [More]
ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar High Tech Center, the Russian pharmaceutical investment and R&D group, and Lancet, Russian Distribution Company, have announced collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry. [More]
Study looks at dabigatran adherence across Veterans Health Administration sites

Study looks at dabigatran adherence across Veterans Health Administration sites

Among patients with atrial fibrillation who filled prescriptions for the anticoagulant dabigatran at Veterans Health Administration sites, there was variability in patient medication adherence across sites, with appropriate patient selection and pharmacist-led monitoring associated with greater adherence to the medication, according to a study in the April 14 issue of JAMA. [More]

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune announced today that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system... [More]
Itraconazole drug shows potential in cancer treatment

Itraconazole drug shows potential in cancer treatment

A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience. [More]
Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

AbbVie today announced that the Japanese Ministry of Health, Labour and Welfare has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir. [More]
New herbal tea to treat malaria in Africa

New herbal tea to treat malaria in Africa

Malaria is a critical health problem in West Africa, where traditional medicine is commonly used alongside modern healthcare practices. An herbal remedy derived from the roots of a weed, which was traditionally used to alleviate malarial symptoms, was combined with leaves and aerial portions from two other plants with antimalarial activity, formulated as a tea, and eventually licensed and sold as an antimalarial phytomedicine. [More]
Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products. [More]
SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug. [More]
Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. [More]

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd. [More]
Sanofi introduces new probiotic supplement for children in South Korea

Sanofi introduces new probiotic supplement for children in South Korea

Sanofi launches a new probiotic supplement for kids in South Korea. Released, in Costco stores under the global Cenovis Kids brand, the new supplement with a delicious vanilla flavor and teddy bear shape is produced by Anlit Ltd., Israel, and designed specifically for kids. [More]
Humabs BioMed reports clinical milestone in medImmune partnership

Humabs BioMed reports clinical milestone in medImmune partnership

Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that a novel antibody developed through its proprietary Cellclone technology will be investigated for the treatment of influenza A... [More]
Amway named Company of the Year by IFANCA for halal-certified Nutrilite products

Amway named Company of the Year by IFANCA for halal-certified Nutrilite products

The Islamic Food and Nutrition Council of America named Amway as Company of the Year during the 2015 International Halal Food Conference for excellence in compliance and execution of halal-certified Nutrilite products in markets around the world. [More]
Studies reveal that dietary supplement can improve reproductive health

Studies reveal that dietary supplement can improve reproductive health

Current statistics on U.S. birth rates from the Centers for Disease Control and Prevention report a continued trend toward delayed motherhood. As fertility gradually declines in the 30s, particularly after age 35, the risk of experiencing difficulty conceiving may increase. In addition to age, there are other common reasons why women may experience difficulties conceiving, including: irregular ovulation cycles and poor egg quality, which may be associated with stress, lifestyle or poor diet. [More]
Penn researchers receive 2015 Vaccine Industry Excellence Award

Penn researchers receive 2015 Vaccine Industry Excellence Award

The laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania, received the 2015 Vaccine Industry Excellence Award for Best Academic Research Team, at the World Vaccine Congress in Washington, DC this week. [More]
Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

A new study finds that effective new hepatitis C drugs are so expensive the state of Rhode Island would have to spend almost twice its entire prison health budget to treat all its chronically infected inmates. [More]
Advertisement
Advertisement